Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer.

Juvekar A, Burga LN, Hu H, Lunsford EP, Ibrahim YH, Balmañà J, Rajendran A, Papa A, Spencer K, Lyssiotis CA, Nardella C, Pandolfi PP, Baselga J, Scully R, Asara JM, Cantley LC, Wulf GM.

Cancer Discov. 2012 Nov;2(11):1048-63. doi: 10.1158/2159-8290.CD-11-0336. Epub 2012 Aug 22.

2.

PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition.

Ibrahim YH, García-García C, Serra V, He L, Torres-Lockhart K, Prat A, Anton P, Cozar P, Guzmán M, Grueso J, Rodríguez O, Calvo MT, Aura C, Díez O, Rubio IT, Pérez J, Rodón J, Cortés J, Ellisen LW, Scaltriti M, Baselga J.

Cancer Discov. 2012 Nov;2(11):1036-47. doi: 10.1158/2159-8290.CD-11-0348. Epub 2012 Aug 22.

3.

Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.

Wang D, Li C, Zhang Y, Wang M, Jiang N, Xiang L, Li T, Roberts TM, Zhao JJ, Cheng H, Liu P.

Gynecol Oncol. 2016 Sep;142(3):548-56. doi: 10.1016/j.ygyno.2016.07.092. Epub 2016 Jul 15.

PMID:
27426307
4.

The promise of combining inhibition of PI3K and PARP as cancer therapy.

Rehman FL, Lord CJ, Ashworth A.

Cancer Discov. 2012 Nov;2(11):982-4. doi: 10.1158/2159-8290.CD-12-0433.

5.

Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancer.

Heerma van Voss MR, Brilliant JD, Vesuna F, Bol GM, van der Wall E, van Diest PJ, Raman V.

Med Oncol. 2017 Mar;34(3):33. doi: 10.1007/s12032-017-0889-2. Epub 2017 Jan 30.

PMID:
28138868
6.

Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.

De P, Sun Y, Carlson JH, Friedman LS, Leyland-Jones BR, Dey N.

Neoplasia. 2014 Jan;16(1):43-72. Erratum in: Neoplasia. 2014 Apr;16(4):375. Neoplasia. 2014 Apr;16(4):375.

7.

Response of subtype-specific human breast cancer-derived cells to poly(ADP-ribose) polymerase and checkpoint kinase 1 inhibition.

Shibata H, Miuma S, Saldivar JC, Huebner K.

Cancer Sci. 2011 Oct;102(10):1882-8. doi: 10.1111/j.1349-7006.2011.02016.x. Epub 2011 Jul 21.

8.

Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models.

Clark CC, Weitzel JN, O'Connor TR.

Mol Cancer Ther. 2012 Sep;11(9):1948-58. doi: 10.1158/1535-7163.MCT-11-0597. Epub 2012 Jul 9.

9.

A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity.

McMullin RP, Wittner BS, Yang C, Denton-Schneider BR, Hicks D, Singavarapu R, Moulis S, Lee J, Akbari MR, Narod SA, Aldape KD, Steeg PS, Ramaswamy S, Sgroi DC.

Breast Cancer Res. 2014 Mar 14;16(2):R25. doi: 10.1186/bcr3625.

10.

Antitumor and anticancer stem cell activity of a poly ADP-ribose polymerase inhibitor olaparib in breast cancer cells.

Shimo T, Kurebayashi J, Kanomata N, Yamashita T, Kozuka Y, Moriya T, Sonoo H.

Breast Cancer. 2014 Jan;21(1):75-85. doi: 10.1007/s12282-012-0356-z. Epub 2012 Mar 28.

PMID:
22454224
11.

Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.

Jang NY, Kim DH, Cho BJ, Choi EJ, Lee JS, Wu HG, Chie EK, Kim IA.

BMC Cancer. 2015 Mar 3;15:89. doi: 10.1186/s12885-015-1090-7.

12.
13.

Co-treatment with BEZ235 Enhances Sensitivity of BRCA1-negative Breast Cancer Cells to Olaparib.

Yi YW, Park JS, Kwak SJ, Seong YS.

Anticancer Res. 2015 Jul;35(7):3829-38.

PMID:
26124328
14.

Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer.

Cardnell RJ, Feng Y, Mukherjee S, Diao L, Tong P, Stewart CA, Masrorpour F, Fan Y, Nilsson M, Shen Y, Heymach JV, Wang J, Byers LA.

PLoS One. 2016 Apr 7;11(4):e0152584. doi: 10.1371/journal.pone.0152584. eCollection 2016.

15.

Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines.

Pierce A, McGowan PM, Cotter M, Mullooly M, O'Donovan N, Rani S, O'Driscoll L, Crown J, Duffy MJ.

Cancer Biol Ther. 2013 Jun;14(6):537-45. doi: 10.4161/cbt.24349.

16.

[PARP inhibitors--theoretical basis and clinical application].

Dębska S, Kubicka J, Czyżykowski R, Habib M, Potemski P.

Postepy Hig Med Dosw (Online). 2012 May 30;66:311-21. Review. Polish.

17.

Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer.

García-Parra J, Dalmases A, Morancho B, Arpí O, Menendez S, Sabbaghi M, Zazo S, Chamizo C, Madoz J, Eroles P, Servitja S, Tusquets I, Yelamos J, Lluch A, Arribas J, Rojo F, Rovira A, Albanell J.

Eur J Cancer. 2014 Oct;50(15):2725-34. doi: 10.1016/j.ejca.2014.07.004. Epub 2014 Aug 12.

PMID:
25128455
18.

PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy.

Domagala P, Huzarski T, Lubinski J, Gugala K, Domagala W.

Breast Cancer Res Treat. 2011 Jun;127(3):861-9. doi: 10.1007/s10549-011-1441-2. Epub 2011 Mar 17.

PMID:
21409392
19.

CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.

Vora SR, Juric D, Kim N, Mino-Kenudson M, Huynh T, Costa C, Lockerman EL, Pollack SF, Liu M, Li X, Lehar J, Wiesmann M, Wartmann M, Chen Y, Cao ZA, Pinzon-Ortiz M, Kim S, Schlegel R, Huang A, Engelman JA.

Cancer Cell. 2014 Jul 14;26(1):136-49. doi: 10.1016/j.ccr.2014.05.020. Epub 2014 Jul 4.

20.

Advances in PARP inhibitors for the treatment of breast cancer.

Dizdar O, Arslan C, Altundag K.

Expert Opin Pharmacother. 2015;16(18):2751-8. doi: 10.1517/14656566.2015.1100168. Epub 2015 Oct 20. Review.

PMID:
26485111

Supplemental Content

Support Center